Evidence map›Paper›PMID 40038202›Full record

ArticleNeurochemical research2025

Systemic Neuroprotection by Chlorogenic Acid: Antioxidant and Anti-inflammatory Evaluation in Early Neurodegeneration Induced by 3-Nitropropionic Acid in Mice.

Angélica Cantero-Téllez, Leticia Moreno-Fierros, Gabriel Gutiérrez-Ospina, Ana Cecilia Santiago-Prieto, Imelda Juárez, Miriam Rodríguez-Sosa, Elizabeth Hernández-Echeagaray

Abstract read
In one paragraph

Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angélica Cantero-TéllezFacultad de Estudios Superiores Iztacala, Unidad de Investigación en Biomedicina, Universidad Nacional Autónoma de México, Av. de los Barrios #1, Los Reyes Iztacala, 54090, Tlalnepantla de Baz, Estado de México, México.
Leticia Moreno-FierrosFacultad de Estudios Superiores Iztacala, Unidad de Investigación en Biomedicina, Universidad Nacional Autónoma de México, Av. de los Barrios #1, Los Reyes Iztacala, 54090, Tlalnepantla de Baz, Estado de México, México.
Gabriel Gutiérrez-OspinaDepartamento de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito, Mario de La Cueva S/N, C.U., Coyoacán, 04510, Ciudad de México, México.
Ana Cecilia Santiago-PrietoLaboratorio de Anatomía Patológica, Hospital H+Querétaro, Privada Ignacio Zaragoza 16, Centro, 76000, Santiago de Querétaro, Qro, Mexico.
Imelda JuárezFacultad de Estudios Superiores Iztacala, Unidad de Investigación en Biomedicina, Universidad Nacional Autónoma de México, Av. de los Barrios #1, Los Reyes Iztacala, 54090, Tlalnepantla de Baz, Estado de México, México.
Miriam Rodríguez-SosaFacultad de Estudios Superiores Iztacala, Unidad de Investigación en Biomedicina, Universidad Nacional Autónoma de México, Av. de los Barrios #1, Los Reyes Iztacala, 54090, Tlalnepantla de Baz, Estado de México, México.
Elizabeth Hernández-EcheagarayFacultad de Estudios Superiores Iztacala, Unidad de Investigación en Biomedicina, Universidad Nacional Autónoma de México, Av. de los Barrios #1, Los Reyes Iztacala, 54090, Tlalnepantla de Baz, Estado de México, México. aehe67@gmail.com.

Funding

Dirección General de Asuntos del Personal Académico- Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, DGAPA-PAPIIT Grant No. 216721
6 · The paper itself

Abstract

Neurodegeneration is characterized by the progressive loss of neurons commonly attributed to neurological causes. Studies published over the past two decades suggest that neurodegeneration may occur due to systemic diseases that compromise energy metabolism throughout the body. This metabolic imbalance develops over decades before neurodegeneration is clinically documented or inferred. It is now accepted that long-lasting oxidative stress and inflammation link neurodegeneration with altered energy metabolism in the body. Systemic prevention of these factors may reduce the odds of developing neurodegeneration and delay or prevent its progression as individuals age. Chlorogenic acid (CGA) is a polyphenol prevalent in fruits and vegetables that exhibits antioxidant and anti-inflammatory properties. It may serve as a systemic neuroprotectant when consumed regularly before the onset of neurodegeneration. To test this possibility, an experimental model of striatal early neurodegeneration induced by systemic administration of 3-nitropropionic acid (3-NP) was used. This toxin inhibits succinate dehydrogenase (SDH), disrupts electron flow and leads to increased production of reactive oxygen species (ROS) and a pro-inflammatory environment. The severity of symptoms induced by 3-NP varies depending on dosage, duration of exposure and administration route. In the brain, 3-NP affects striatal medium spiny neurons in the basal ganglia and in less degree pyramidal neurons from frontal cortex, a feature observed in Huntington's disease (HD). The aim of this study was to investigate the antioxidant and anti-inflammatory properties of CGA in the 3-NP-induced model of early neurodegeneration. Systemic administration of CGA significantly reduced lipid peroxidation and promoted an anti-inflammatory profile in the brain when co-administered with 3-NP. These results support that CGA could serve as a systemic neuroprotectant in individuals challenged by environmental toxins that disrupt mitochondrial function.

Indexed as

Anti-Inflammatory AgentsAntioxidantsChlorogenic AcidNeurodegenerative DiseasesNeuroprotectionNeuroprotective AgentsNitro CompoundsPropionatesAnimalsMaleMiceMice, Inbred C57BLOxidative Stress3-nitropropionic acidAnti-Inflammatory AgentsAntioxidantsChlorogenic AcidNeuroprotective AgentsNitro CompoundsPropionatesBasal gangliaEnvironmental toxinsHuntington’s diseaseLipid peroxidationMitochondrial dysfunctionNeuroprotectionPolyphenols

Identifiers

PMID40038202
PMCPMC11880071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.